 |
|
Progression Rates of Cytomegalovirus Retinopathy in Ganciclovir-Treated and Untreated Patients
Gary N. Holland, MD;
James D. Shuler, MD
Arch Ophthalmol. 1992;110(10):1435-1442.
Abstract
• Cytomegalovirus retinopathy lesions in patients with the acquired immunodeficiency syndrome may continue to enlarge despite ganciclovir sodium treatment. In an historical cohort study, we used serial, masked retinal photographs to calculate progression rates for 14 ganciclovirtreated patients known to have disease progression and for 17 untreated patients. The median period of evaluation was 23.5 days for ganciclovir-treated patients and 28 days for untreated patients (P=.89). In both groups, the rate at which borders of preexisting lesions advanced into uninfected retina varied in different directions. Anterior progression rates were usually faster than posterior progression rates. The median progression rate with which disease approached the fovea in ganciclovir-treated patients was 11.5 µm/d (range, 0 to 25.0 µm/d) and the median progression rate for untreated patients was 24.0 µm/d (range, 0 to 164.0 µm/d) (P=.01). These results suggest that ganciclovir provides a therapeutic benefit for patients with progressive disease by slowing the rate with which infection spreads. The size and appearance of lesions may also be related to their response to treatment and to progression rates of untreated disease.
Author Affiliations
From the UCLA Ocular Inflammatory Disease Center, Jules Stein Eye Institute, the Department of Ophthalmology (Drs Holland and Shuler), and the UCLA Clinical AIDS Research and Education (CARE) Center (Dr Holland), UCLA School of Medicine. Drs Holland and Shuler have no proprietary interest in ganciclovir.
Footnotes
Accepted for publication March 13, 1992.
Presented in part at the annual meeting of the Association for Research in Vision and Ophthalmology, Sarasota, Fla, May 3, 1990.
Reprint requests to Jules Stein Eye Institute, 100 Stein Plaza, UCLA, Los Angeles, CA 90024-7003 (Dr Holland).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
The Double-Edged Ocular Immune Response: The Cogan Lecture
Whitcup
IOVS 2000;41:3243-3248.
FULL TEXT
Risk Factors for Advancement of Cytomegalovirus Retinitis in Patients With Acquired Immunodeficiency Syndrome
Holbrook et al.
Arch Ophthalmol 2000;118:1196-1204.
ABSTRACT
| FULL TEXT
Cytomegalovirus Retinitis in the Era of Highly Active Antiretroviral Therapy
Whitcup
JAMA 2000;283:653-657.
ABSTRACT
| FULL TEXT
Iritis and Hypotony After Treatment With Intravenous Cidofovir for Cytomegalovirus Retinitis
Davis et al.
Arch Ophthalmol 1997;115:733-737.
ABSTRACT
Use of the Ganciclovir Implant in the Treatment of Recurrent Cytomegalovirus Retinitis
Marx et al.
Arch Ophthalmol 1996;114:815-820.
ABSTRACT
|
